MX2023010541A - Proteinas de union al antigeno del peptido del mhc mage-a4. - Google Patents
Proteinas de union al antigeno del peptido del mhc mage-a4.Info
- Publication number
- MX2023010541A MX2023010541A MX2023010541A MX2023010541A MX2023010541A MX 2023010541 A MX2023010541 A MX 2023010541A MX 2023010541 A MX2023010541 A MX 2023010541A MX 2023010541 A MX2023010541 A MX 2023010541A MX 2023010541 A MX2023010541 A MX 2023010541A
- Authority
- MX
- Mexico
- Prior art keywords
- mage
- binding proteins
- antigen binding
- peptide
- mhc antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163158691P | 2021-03-09 | 2021-03-09 | |
| US202163172864P | 2021-04-09 | 2021-04-09 | |
| PCT/IB2022/052119 WO2022190009A1 (en) | 2021-03-09 | 2022-03-09 | Mage-a4 peptide-mhc antigen binding proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023010541A true MX2023010541A (es) | 2023-11-24 |
Family
ID=80787264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023010541A MX2023010541A (es) | 2021-03-09 | 2022-03-09 | Proteinas de union al antigeno del peptido del mhc mage-a4. |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11912771B2 (https=) |
| EP (1) | EP4304726A1 (https=) |
| JP (1) | JP2024509910A (https=) |
| KR (1) | KR20230169944A (https=) |
| AU (1) | AU2022233285A1 (https=) |
| CA (1) | CA3210289A1 (https=) |
| MX (1) | MX2023010541A (https=) |
| WO (1) | WO2022190009A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023010541A (es) | 2021-03-09 | 2023-11-24 | Cdr Life Ag | Proteinas de union al antigeno del peptido del mhc mage-a4. |
| US12435444B2 (en) | 2021-03-09 | 2025-10-07 | Cdr-Life Ag | Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same |
| MX2024007473A (es) | 2021-12-14 | 2024-09-10 | Cdr Life Ag | Activador del linfocito t dirigido al mhc doble. |
| CA3264474A1 (en) | 2022-09-14 | 2024-03-21 | Cdr-Life Ag | MAGE-A4 DOUBLE T LYMPHOCYTE ENGAGEMENT |
| CN119490592B (zh) * | 2023-08-14 | 2025-11-18 | 东莞市朋志生物科技有限公司 | 一种抗κ型轻链抗体及其应用 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7199231B1 (en) | 1991-05-23 | 2007-04-03 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-4 and 41 and uses thereof |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| WO2000020445A2 (en) | 1998-10-02 | 2000-04-13 | Ludwig Institute For Cancer Research | Tumor antigens and ctl clones isolated by a novel procedure |
| US7311914B2 (en) | 2002-08-13 | 2007-12-25 | Ludwig Institute For Cancer Research | MAGE-A4 antigenic peptides and uses thereof |
| WO2004016740A2 (en) | 2002-08-15 | 2004-02-26 | Epitomics, Inc. | Humanized rabbit antibodies |
| AU2003259718A1 (en) | 2003-08-07 | 2005-03-07 | Epitomics, Inc. | Methods for humanizing rabbit monoclonal antibodies |
| US7807392B1 (en) | 2003-09-15 | 2010-10-05 | Celera Corporation | Lung disease targets and uses thereof |
| JP5276846B2 (ja) | 2005-09-13 | 2013-08-28 | 国立大学法人三重大学 | Ｔ細胞レセプターをコードする核酸が挿入されてなるベクター及び該レセプターを発現する細胞 |
| RU2009137582A (ru) | 2007-03-12 | 2011-04-20 | Эсбатек Аг (Ch) | Инженерия и оптимизация одноцепочечных антител на основе последовательности |
| KR20170036814A (ko) | 2007-05-21 | 2017-04-03 | 앨더바이오 홀딩스 엘엘씨 | 신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체 |
| EP2164961B1 (en) | 2007-06-25 | 2015-01-07 | ESBATech, an Alcon Biomedical Research Unit LLC | Sequence based engineering and optimization of single chain antibodies |
| BRPI0813645A2 (pt) | 2007-06-25 | 2014-12-30 | Esbatech Alcon Biomed Res Unit | Métodos para modificar anticorpos, e anticorpos modificados com propriedades funcionais aperfeiçoadas |
| CA2728829C (en) | 2008-06-25 | 2018-01-02 | Esbatech, An Alcon Biomedical Research Unit Llc | Solubility optimization of immunobinders |
| PL2307458T3 (pl) | 2008-06-25 | 2018-08-31 | Esbatech, An Alcon Biomedical Research Unit Llc | Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała |
| BR112012004546A8 (pt) * | 2009-08-29 | 2017-12-05 | Abbott Lab | Terapêutica por proteínas ligantes dll4-ligantes |
| WO2013048243A1 (en) | 2011-09-29 | 2013-04-04 | Apo-T B.V. | Multi-specific binding molecules targeting aberrant cells |
| EP3223907A2 (en) | 2014-11-26 | 2017-10-04 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd38 |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| DK3440106T3 (da) * | 2016-04-08 | 2021-10-04 | Adaptimmune Ltd | T-cellereceptorer |
| SMT202200306T1 (it) | 2016-04-08 | 2022-09-14 | Immunocore Ltd | Recettori di cellule t |
| BR112018070637A2 (pt) | 2016-04-08 | 2019-02-05 | Adaptimmune Ltd | receptores de células t |
| WO2017201493A1 (en) | 2016-05-20 | 2017-11-23 | Harpoon Therapeutics, Inc. | Single chain variable fragment cd3 binding proteins |
| EP3509635A1 (en) * | 2016-09-06 | 2019-07-17 | Vavotar Life Sciences LLC | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
| US10859566B2 (en) | 2017-03-20 | 2020-12-08 | Genocea Biosciences, Inc. | Treatment methods |
| WO2018225732A1 (ja) * | 2017-06-05 | 2018-12-13 | 国立大学法人三重大学 | Ｍａｇｅ－ａ４由来ペプチドを認識する抗原結合性タンパク質 |
| US20210147550A1 (en) | 2017-08-18 | 2021-05-20 | Joshua Michael Francis | Antigen-binding proteins targeting shared antigens |
| EP3731876A4 (en) | 2017-12-28 | 2022-04-06 | Gritstone bio, Inc. | ANTIGEN-BINDING PROTEINS TARGETING SHARED ANTIGENS |
| GB201803750D0 (en) | 2018-03-08 | 2018-04-25 | Immunocore Ltd | Method |
| JP7326764B2 (ja) | 2018-03-09 | 2023-08-16 | 東ソー株式会社 | 腫瘍マーカーならびに腫瘍細胞を夾雑細胞と区別して回収および検出する方法 |
| CA3102254A1 (en) | 2018-06-04 | 2019-12-12 | Apo-T B.V. | Methods and means for attracting immune effector cells to tumor cells |
| CN108866098A (zh) | 2018-07-27 | 2018-11-23 | 北京安斯晨睿生物科技有限公司 | 携带mage-a4突变抗原基因的重组腺相关病毒载体及其构建方法与应用 |
| GB201819540D0 (en) | 2018-11-30 | 2019-01-16 | Adaptimmune Ltd | T cell modification |
| GB201901306D0 (en) | 2019-01-30 | 2019-03-20 | Immunocore Ltd | Multi-domain binding molecules |
| EP3714941A1 (en) * | 2019-03-27 | 2020-09-30 | Medigene Immunotherapies GmbH | Mage-a4 tcrs |
| PH12021553152A1 (en) | 2019-06-18 | 2022-08-15 | Regeneron Pharma | Mage-a4 t cell receptors and methods of use thereof |
| EP4004049A1 (en) | 2019-07-24 | 2022-06-01 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors with mage-a4 specificity and uses thereof |
| DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| CN110333352A (zh) | 2019-08-07 | 2019-10-15 | 基因科技（上海）股份有限公司 | 肿瘤相关自身抗体及肿瘤标志物联合检测试剂盒 |
| KR20220100963A (ko) | 2019-12-18 | 2022-07-18 | 에프. 호프만-라 로슈 아게 | Hla-a2/mage-a4에 결합하는 항체 |
| EP4139347A4 (en) | 2020-04-24 | 2024-06-05 | Memorial Sloan Kettering Cancer Center | Anti-cd3 antibodies and uses thereof |
| CN116096754A (zh) | 2020-05-04 | 2023-05-09 | 免疫里森公司 | 前体三特异性抗体构建体及其使用方法 |
| EP4149631A1 (en) | 2020-05-13 | 2023-03-22 | Adaptimmune Limited | Method of treatment of cancer or tumour |
| US20230190803A1 (en) | 2020-05-13 | 2023-06-22 | Adaptimmune Limited | Method of treatment of cancer or tumour |
| CN114524878B (zh) | 2020-11-23 | 2024-08-02 | 康诺亚生物医药科技（成都）有限公司 | 一种双特异性抗体及其用途 |
| US12435444B2 (en) | 2021-03-09 | 2025-10-07 | Cdr-Life Ag | Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same |
| MX2023010541A (es) | 2021-03-09 | 2023-11-24 | Cdr Life Ag | Proteinas de union al antigeno del peptido del mhc mage-a4. |
| AU2022271212A1 (en) | 2021-05-04 | 2023-11-30 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors with mage-a4 specificity and uses thereof |
| WO2022262678A1 (zh) | 2021-06-15 | 2022-12-22 | 盛禾(中国)生物制药有限公司 | 一种多特异性抗原结合蛋白及其应用 |
| US20240327543A1 (en) | 2021-08-02 | 2024-10-03 | Shenghe (China) Biopharmaceutical Co., Ltd. | Multispecific antigen-binding protein and use thereof |
| CN117730103A (zh) | 2021-08-02 | 2024-03-19 | 盛禾(中国)生物制药有限公司 | 一种多特异性抗原结合蛋白及其应用 |
| EP4380631A4 (en) | 2021-08-04 | 2025-06-25 | Abpro Corporation | Cd3 targeting antibodies and uses thereof |
| EP4377360A4 (en) | 2021-09-17 | 2025-10-15 | Adimab Llc | Anti-cd3 antibodies |
-
2022
- 2022-03-09 MX MX2023010541A patent/MX2023010541A/es unknown
- 2022-03-09 EP EP22711322.2A patent/EP4304726A1/en active Pending
- 2022-03-09 KR KR1020237031175A patent/KR20230169944A/ko active Pending
- 2022-03-09 JP JP2023555203A patent/JP2024509910A/ja active Pending
- 2022-03-09 WO PCT/IB2022/052119 patent/WO2022190009A1/en not_active Ceased
- 2022-03-09 US US17/690,526 patent/US11912771B2/en active Active
- 2022-03-09 CA CA3210289A patent/CA3210289A1/en active Pending
- 2022-03-09 AU AU2022233285A patent/AU2022233285A1/en active Pending
-
2024
- 2024-01-04 US US18/404,536 patent/US20240279344A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4304726A1 (en) | 2024-01-17 |
| KR20230169944A (ko) | 2023-12-18 |
| JP2024509910A (ja) | 2024-03-05 |
| CA3210289A1 (en) | 2022-09-15 |
| US20220380472A1 (en) | 2022-12-01 |
| WO2022190009A1 (en) | 2022-09-15 |
| AU2022233285A1 (en) | 2023-10-19 |
| US11912771B2 (en) | 2024-02-27 |
| US20240279344A1 (en) | 2024-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023010541A (es) | Proteinas de union al antigeno del peptido del mhc mage-a4. | |
| WO2019236749A3 (en) | Methods and applications of protein identification | |
| WO2019036055A3 (en) | METHODS OF SELECTING BINDING REAGENTS | |
| EP4365597A3 (en) | Methods of assaying proteins | |
| EP4442706A3 (en) | Canine antibody libraries | |
| ZA202005260B (en) | Activatable antibodies and methods of making and using thereof | |
| ZA202000027B (en) | Constructs specifically recognizing glypican 3 and uses thereof | |
| CY1122494T1 (el) | Πρωτεϊνες συντηξης οι οποιες περιλαμβανουν μια πρωτεϊνη δεσμευσης και ενα πολυπεπτιδιο ιντερλευκινης-15 το οποιο εχει μια μειωμενη συγγενεια για il15ra και θεραπευτικες χρησεις αυτων | |
| PH12019500122A1 (en) | Bispecific antibody-like binding proteins specifically binding to cd3 and cd123 | |
| WO2019241430A3 (en) | Antibody-oligonucleotide conjugates | |
| PH12021553042A1 (en) | Sorting with counter selection using sequence similar peptides | |
| GB2538216A (en) | Method of screening candidate biochemical entities targeting a target biochemical entity | |
| PH12015502278A1 (en) | Novel bispecific binding molecules with antitumoral activity | |
| WO2018076024A3 (en) | Methods for screening b cell lymphocytes | |
| EP4379725A3 (en) | Immune recognition motifs | |
| PT1512014E (pt) | Método de identificação de alo-antigénios e sua utilização para terapia de cancro e transplante | |
| NZ583282A (en) | Human c-fms antigen binding proteins | |
| ZA202309861B (en) | Proteins comprising cd3 antigen binding domains and uses thereof | |
| BRPI0411854A (pt) | veìculos protéicos para vacinas | |
| MX2025011030A (es) | Construcciones de proteinas de union a antigenos y usos de estas | |
| PH12018502293A1 (en) | Humanized anti-basigin antibodies and the use thereof | |
| MX2023009615A (es) | Moleculas de union anti-cd123 y usos de estas. | |
| WO2023086480A3 (en) | Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof | |
| MX2021012030A (es) | Instrumentacion automatizada para la produccion de bibliotecas de peptidos de receptores de celulas t. | |
| MX2025002924A (es) | Activadores duales de linfocitos t con peptido mage-a4 |